FanHouse ChrisLeben

In April, Nate Quarry rebounded from the quickest loss in his career with a dominant first-round victory over Jason MacDonald. Now, the heavy-handed middleweight hopes to make it two in a row, but will need to stop the growing momentum of Tim Credeur, who is on a six-fight win streak. The two square off at UFC Fight Night on Sept. 16.

In this FanHouse interview, Quarry (11-3) candidly talks about the Credeur matchup, his disappointment in losing to Demian Maia, why he'd still take the Rich Franklin fight knowing it would end in infamy, and the best and worst parts of being a fighter at age 37.

Experts who study boring things that aim to depress us say you can't learn anything watching TV. I say "bollocks" (which is a word I learned watching the BBC). Watching UFC 102 with a finely attuned eye, there was much to be learned.

Here's my list of five things I surmised from Saturday night's fights.

After a nine-month suspension for using steroids, UFC middleweight Chris Leben is soon to return to action. Usually in a situation like that, a fighter would have to worry about negative public reaction to his comeback, but in this case, Leben is likely to be hailed as a conquering hero, as the 29-year-old veteran has the good fortune of returning at UFC 102 in his hometown of Portland, Oregon.

The match itself, however will not be easy; Leben (18-6) will take on former three-time NCAA wrestling national champion Jake Rosholt as a featured bout on the televised card.

"The Crippler" recently took a few moments out of his training to talk to FanHouse about his steroids suspension, returning to the octagon, and preparing for Rosholt.

"I am obviously disappointed with Chris, who has made great strides getting his life back on track," said UFC President Dana White. "To his credit, he has taken responsibility for his actions and is accepting the punishment that has been handed down. But as always, the UFC puts the safety of its athletes first and foremost, and we won't tolerate anyone using performance enhancing drugs in our organization."